



In the News:

- On 4/28/2021, the Department of Health and Human Services announced the publication of new **Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder** that provides eligible physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse midwives, who are state licensed and registered by the DEA to prescribe controlled substances, an exemption from certain statutory certification requirements related to training, counseling and other ancillary services (i.e., psychosocial services). The new recommendations address perceived barriers around prescribing buprenorphine by exempting practitioners from the certification requirements related to training, counseling and other ancillary services.
- **Guidance regarding the use of Ketamine and Esketamine:** Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto, and colleagues reviewed the evidence for the prescribing of Ketamine and Esketamine, published online in the American Journal of Psychiatry, “Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.” The authors have developed a check the “implementation checklist” providing guidance for the safe administration of Ketamine and Esketamine.
- **FDA approves new treatment for ADHD in Pediatric Patients:** Quelbree (viloxazine extended-release capsule) for the treatment of ADHD in pediatric patients 6 to 17 years of age.